Linagliptin (Trajenta®) 5 mg film-coated tablets
All Wales Medicines Strategy Group (AWMSG)
Record ID 32013000418
English
Authors' recommendations:
Linagliptin (Trajenta®) is recommended as an option for use within NHS Wales for the treatment of type 2 diabetes mellitus to improve glycaemic control in adults:
as monotherapy:
in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment;
as combination therapy:
in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;
in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control; and
in combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
http://www.wales.nhs.uk/sites3/Documents/371/linagliptin%20%28Trajenta%29%201667%20FAR.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Hypoglycemic Agents
- Dipeptidyl-Peptidase IV Inhibitors
- Diabetes Mellitus, Type 2
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.